GlaxoSmithKline and Lonza have entered into a new agreement under which Lonza will support the ongoing development of GSK’s biopharmaceutical pipeline by supplying manufacturing capacity for five early stage monoclonal antibodies. Terms were not disclosed, but Lonza will initially manufacture clinical trial batches of five compounds currently in Phase I and II for GSK. Lonza will also provide access to flexible capacity to enable GSK to respond to future demand for late-stage development and ...